Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media
Molecular Mechanisms of Head and Neck Tumors

Research Group Molecular Mechanisms of Head and Neck Tumors

PD Dr. Jochen Heß

Immunohistochemical staining of a HNSCC tissue section demonstrates infiltrating immune cells (brown signal) in the tumor stroma.
© dkfz.de

Head and neck cancer is one of the most frequent and dismal human malignancies with so far limited therapeutic options. The majority represents squamous cell carcinoma (HNSCC) arising from the epithelium lining the sinonasal tract, oral cavity, pharynx and larynx. HNSCC has long been a treatment challenge due to the high rate of recurrence and local metastasis. Hence, the identification for novel prognostic biomarkers to objectively predict patients with high risk for tumor relapse and the development of more effective and less toxic treatment modalities are eagerly awaited. Similar to other solid tumors HNSCC development is a complex multistep process characterized by the accumulation of genetic and epigenetic alteration. Our research program is based on functional genomic and proteome analyses as well as experimental studies using human tumor samples, preclinical mouse tumor models and cell lines derived thereof, and focuses on: (i) topological characteristics of signaling and gene regulatory networks in the pathogenesis of HNSCC, (ii) molecular mechanisms underlying the establishment and maintenance of tumor recurrence, and (iii) the role of the pro-inflammatory microenvironment in HNSCC. The major aim of our studies is the identification of novel molecular biomarkers and putative drug targets for translational cancer research.

Although the principle risk factors for HNSCC remain tobacco and alcohol use, human papilloma virus infection has recently been found to be etiologically associated with 20-25% of HNSCC, espacially in the oropharynx. Strikingly, the majority of HNSCC patients harboring HPV-positive carcinomas presents with an advanced stage of the disease at the time of diagnose; however, there is growing evidence that these patients have a favorable prognosis independent of the therapeutic treatment regimen. We propose that a systematic analysis of HPV-negative and HPV-positive oropharyngeal squamous cell carcinomas will not only enhance our knowledge on the impact of HPV infection on neoplastic transformation, but could also improve strategies of cancer prevention and therapy. Tumor development and progression is not driven exclusively by the accumulation of genetic and epigenetic changes in cancer cells, but rather requires a permissive and supportive tumor microenvironment, which may be favored by chronic inflammation, a state often preceding the development of cancer. Indeed, numerous studies demonstrated that most HNSCCs are highly inflammatory in nature and express a plethora of pro-inflammatory mediators. In order to address the impact of an inflammatory microenvironment on the pathogenesis of HNSCC and to proof the concept whether pharmaceutical targeting of inflammation serves as an innovative option for tumor prevention or therapy, we will continue to establish and investigate preclinical mouse tumor models.

Contact

PD Dr. Jochen Heß
Molecular Mechanisms of Head and Neck Tumors (E221)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 4500

Selected Publications

  • Gebhardt C., Riehl A., Durchdewald M., Nemeth J., Furstenberger G., Muller-Decker K., Enk A., Arnold B., Bierhaus A., Nawroth P.P., Hess J. & Angel P. (2008). RAGE signaling sustains
  • Nemeth J., Stein I., Haag D., Riehl A., Longerich T., Horwitz E., Breuhahn K., Gebhardt C., Schirmacher P., Hahn M., Ben-Neriah Y., Pikarsky E., Angel P. & Hess J. (2009). S100A8 and S100A9
  • Riehl A., Bauer T., Brors B., Busch H., Mark R., Nemeth J., Gebhardt C., Bierhaus A., Nawroth P., Eils R., Konig R., Angel P. & Hess J. (2010). Identification of the Rage-dependent gene regulatory network
  • Riehl A., Nemeth J., Angel P. & Hess J. (2009). The receptor RAGE: Bridging inflammation and cancer. Cell Commun. Signal., 7, 12
to top
powered by webEdition CMS